GRIB. Research Unit on Biomedical Informatics





News & activities

A webserver to study the protein networks perturbed in diseases

Researchers from the UPF, IMIM and UVIC have developed the website GUILDify to study the molecular environment of the proteins involved in diseases. The website is a promising tool to study the molecular mechanisms underlying a disease, to understand the relationships between two diseases and to propose potential drugs for their treatment.

Quim Aguirre, PhD student at the Structural Bioinformatics Group (SBI) of GRIB, behind this project, tells us all about it in an article on the El·lipse website.

More info...

New approaches of chemical safety assessment discussed between regulatory experts and the researchers of EU-ToxRisk

An international workshop, held in Espoo (Fin), close to the headquarters of the European Chemicals Agency (ECHA), paved the way for a new risk assessment strategy, relying less on animal data, and using multi-dimensional information from many sources in the so-called read-across procedure.

The event took place on 21-22 May 2019 and was organised by EU-ToxRisk, in close collaboration with regulatory representatives from several European agencies (ECHA, EFSA, SCCS), US agencies (NTP, EPA), and other organisations (OECD, Health Canada, NIHS Japan).

EU-ToxRisk - An Integrated European 'Flagship' Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century - is a research project receiving funding from the European Union's Horizon 2020 research and innovation programme. Its main goal is to increase confidence in the implementation of non-animal approaches into the regulatory decision-making process for hazard and risk assessment. For this purpose, the project works on the development, evaluation and implementation of animal-free New Approach Methods (NAM) in modern toxicology.  GRIB participates on this project, in particular, the PharmacoInformatics group of GRIB is leading the development of computational tools which will facilitate the use of NAM in read accross studies.

More info...

More news RSS

Last project

PSYBIAS

A novel paradigm for effective and safer treatment of schizophrenia: biased (ANT) agonists with a characterized polypharmacological profile. The project is funded by the H2020 ERA-NET NEURON project for the period 2019-2021 and is coordinated by the GRIB.

More projects

Last publications

More publications



Site Information